SARS-CoV-2 Donor-Recipient Immunity Transfer

Plain-language summary

This study investigated whether immunity against SARS-CoV-2 is transferred from donor to recipient in patients undergoing allogeneic hematopoietic cell transplant, using blood and saliva samples and medical record review. Patients scheduled for an allogeneic stem cell transplant because of blood cancers (hematologic malignancies) such as lymphoma, leukemia, or myelodysplastic syndrome took part. This study without an assigned phase has been carried out and is completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

City of Hope Medical Center

Intervention

Biospecimen Collection, Diagnostic Laboratory Biomarker Analysis, Electronic Health Record Review, Questionnaire Administration

Start date

9/23/2020

Estimated completion

5/5/2023

Countries

United States

Related genes

Locations

• Duarte, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* ALL COHORTS: Documented written informed consent of the participant
* ALL COHORTS: Recipients must have a planned allogeneic HCT procedure. MRD, MUD, and haplo HCT allowed. Usage of post-transplant cyclophosphamide (PTCy) permitted only in haplo setting
* ALL COHORTS: GCSF-mobilized peripheral blood stem cell (PBSC) only as graft source
* ALL COHORTS: Planned HCT with minimal to no-T cell depletion of graft for the treatment of the following hematologic malignancies:

  * Lymphoma (Hodgkin and non-Hodgkin)
  * Myelodysplastic syndrome
  * Acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood. Persistent lymphadenopathy on computed tomography \[CT\] or CT/positron emission tomography \[PET\] scan without progression is allowed)
  * Acute myeloid leukemia in first or second remission
  * Chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase
  * Other hematologic malignancies including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis
* ALL COHORTS: Willingness to

  * Provide blood samples and saliva specimens
  * Permit medical record review
* ADDITIONAL CRITERIA FOR RECIPIENTS IN THE MAIN COHORT:

  * Absence of documented COVID-19 history and active COVID-19 infection
* ADDITIONAL CRITERIA FOR RECIPIENTS IN THE REFERENCE COHORT: Active COVID-19 infection during HCT